CompletedNot Applicable

Prevention of PNX and Haemorrhagic Complications in Diagnostic Percutaneous Lung Biopsy Using the MIPP-Kit Device

Italy40 participantsStarted 2019-02-04

Plain-language summary

The study will assess the safety and feasibility of a new medical device, MIPP-Kit, for the prevention of complications during diagnostic, CT guided ,percutaneous lung needle biopsy.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical indication for diagnostic percutaneous lung biopsy Exclusion Criteria: * Pregnant, or breastfeeding patient (Female) * actively participating in other clinical trials in the previous 30 days * known allergies to the investigational device components * comorbidities that preclude undergoing percutaneous lung biopsy procedure * concomitant treatments that preclude undergoing percutaneous lung biopsy procedure

What they're measuring

Rate of complications associated with percutaneous lung biopsy

Timeframe: 48 hours after procedure

Trial details

NCT IDNCT04071509

SponsorBetaGlue Technologies spa

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-02-27

View on ClinicalTrials.gov More Complications in Diagnostic Percutaneous Lung Biopsy Procedures trials